Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Other Non-Current Assets (2023 - 2025)

Silence Therapeutics' Other Non-Current Assets history spans 3 years, with the latest figure at $399000.0 for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 85.68% to $399000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $399000.0, a 85.68% decrease, with the full-year FY2024 number at $356000.0, down 90.24% from a year prior.
  • Other Non-Current Assets hit $399000.0 in Q3 2025 for Silence Therapeutics, down from $3.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for SLN hit a ceiling of $3.9 million in Q2 2025 and a floor of $356000.0 in Q4 2024.
  • Historically, Other Non-Current Assets has averaged $2.6 million across 3 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 88.88% in 2024 and later skyrocketed 31.3% in 2025.
  • Tracing SLN's Other Non-Current Assets over 3 years: stood at $3.2 million in 2023, then tumbled by 88.88% to $356000.0 in 2024, then grew by 12.08% to $399000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for SLN at $399000.0 in Q3 2025, $3.9 million in Q2 2025, and $3.6 million in Q1 2025.